Loading...

SOHO 2026 Annual Meeting

This website and third-party tools we use rely on cookies for the best user experience. By selecting "I agree", you agree to cookie usage as described in our Privacy Policy.

1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

ePostersLive by SciGen Technologies S.A. All rights reserved.

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Home Posters by Code Posters by Title Authors Affiliations Topics Sessions Videos Audios Previous meetings

Topics

Select Topic

Showing 47 results for "Indolent B-Cell Lymphoma (IBCL)".

Thumbnail for Beyond Hemolysis: Etiologic Diversity and Diagnostic Challenges in Cold Agglutinin Disorders With Implications for Targeted Therapy

IBCL - 478

Beyond Hemolysis: Etiologic Diversity and Diagnostic Challenges in Cold Agglutinin Disorders With Implications for Targeted Therapy

Krisztina Jeszenszky

Poster Presenter: Krisztina Jeszenszky

Thumbnail for Diagnostic Delays and Comparable Response Rates to iMCD-Directed Therapies in Patients With and Without Expert-Confirmed Idiopathic Multicentric Castleman Disease Diagnoses

IBCL - 492

Diagnostic Delays and Comparable Response Rates to iMCD-Directed Therapies in Patients With and Without Expert-Confirmed Idiopathic Multicentric Castleman Disease Diagnoses

Larissa Borys

Poster Presenter: Larissa Borys

Previous 1 2 3 4 5 6 Next

Copyright © 2015-2026, ePostersLive® SciGen is a registered trademark of SciGen Technologies S.A. Patent pending.

Thumbnail for Clinical Characteristics and Survival Outcomes in Waldenstrφm Macroglobulinemia: An Updated Analysis of 10574 Patients From the SEER Database (1975-2020)

IBCL - 510

Clinical Characteristics and Survival Outcomes in Waldenstrφm Macroglobulinemia: An Updated Analysis of 10574 Patients From the SEER Database (1975-2020)

Alamin Mustafa

Poster Presenter: Alamin Mustafa

Thumbnail for Two-Year Rituximab Maintenance vs Observation After First-Line Treatment With Bendamustine Plus Rituximab (B-R) in Patients With Waldenstrφm's Macroglobulinemia: Results of a Prospective, Randomized Multicenter Phase 3 Study (StiL NHL7-2008 MAINTAIN Trial)

IBCL - 549

Two-Year Rituximab Maintenance vs Observation After First-Line Treatment With Bendamustine Plus Rituximab (B-R) in Patients With Waldenstrφm's Macroglobulinemia: Results of a Prospective, Randomized Multicenter Phase 3 Study (StiL NHL7-2008 MAINTAIN Trial)

Mathias Rummel

Poster Presenter: Mathias Rummel

Thumbnail for Administering Tafasitamab, Lenalidomide and Rituximab for Follicular Lymphoma: a Single Institution Experience From the Phase 3 inMIND Study

IBCL - 552

Administering Tafasitamab, Lenalidomide and Rituximab for Follicular Lymphoma: a Single Institution Experience From the Phase 3 inMIND Study

Danielle Janiszewski

Poster Presenter: Danielle Janiszewski

Thumbnail for Racial Disparities in Incidence of Non-Hodgkin Lymphoma as a Second Primary Malignancy Following Prostate Cancer: A Population-Based Study

IBCL - 665

Racial Disparities in Incidence of Non-Hodgkin Lymphoma as a Second Primary Malignancy Following Prostate Cancer: A Population-Based Study

Damilola Ologbe

Poster Presenter: Damilola Ologbe

Thumbnail for Histologic Transformation Drives the Adverse Prognosis of POD24 in a Cohort of Patients With Follicular Lymphoma in Mexico

IBCL - 683

Histologic Transformation Drives the Adverse Prognosis of POD24 in a Cohort of Patients With Follicular Lymphoma in Mexico

Laura Elena Valdovinos-Elizalde

Poster Presenter: Laura Elena Valdovinos-Elizalde

$Thumbnail for Anchored Matching-Adjusted Indirect Comparison of Epcoritamab, Lenalidomide, and Rituximab vs Tafasitamab, Lenalidomide, and Rituximab in Relapsed/Refractory Follicular Lymphoma: EPCORE FL-1 vs inMIND$

IBCL - 740

Anchored Matching-Adjusted Indirect Comparison of Epcoritamab, Lenalidomide, and Rituximab vs Tafasitamab, Lenalidomide, and Rituximab in Relapsed/Refractory Follicular Lymphoma: EPCORE FL-1 vs inMIND

Moshe Levy

Poster Presenter: Moshe Levy

Thumbnail for Retrospective Analysis of Cardiovascular Risk Assessment Prior to BTK Inhibitor Treatment for Patients with CLL and B-cell Lymphomas

IBCL - 907

Retrospective Analysis of Cardiovascular Risk Assessment Prior to BTK Inhibitor Treatment for Patients with CLL and B-cell Lymphomas

Nicholas Demetriou

Poster Presenter: Nicholas Demetriou

ePosters in

Topics Sessions

Acute Lymphoblastic Leukemia (ALL)(71)Acute Myeloid Leukemia (AML)(230)Aggressive B-Cell Lymphoma (ABCL)(114)Cellular Therapy (CT)(128)Chronic Lymphocytic Leukemia (CLL)(110)Chronic Myeloid Leukemia (CML)(55)Hodgkin Lymphoma (HL)(54)Indolent B-Cell Lymphoma (IBCL)(47)Mantle Cell Lymphoma (MCL)(23)Multiple Myeloma (MM)(234)

Previous 1 2 Next

Sponsors